Who founded Glycomine?

Glycomine was founded by Agnes Rafalko in 2014.

Who are Glycomine's investors?

Glycomine's investors include Advent Life Sciences, Asahi Kasei Corporate Venture Capital, Chiesi Ventures, CTI Life Sciences Fund L.P., Mission Bay Capital, Mission Biocapital, Remiges Ventures, Inc., RiverVest Venture Partners and 5 more.

How much funding has Glycomine raised?

Glycomine has disclosed $234.9M raised across 3 of its 5 known rounds.

Where is Glycomine headquartered?

Glycomine is headquartered in San Francisco, US.

Glycomine

San Francisco, US · Founded 2014 · 26 employees on LinkedIn · 13 known investors

Find your way into Glycomine

Paths you didn't know you had: your email and LinkedIn already hold routes to the Glycomine team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options. The company focuses on addressing unmet medical needs in the rare disease space.

Biotech

Founders & leadership

Glycomine was founded in 2014 by Agnes Rafalko.

Agnes RafalkoFounder, Chief Scientific Officer & Chief Executive Officer2014–2019Executive Officer, Director at Glycomine www.glycomine.com

Steven Axon Chief Executive OfficerHe has background in biotech business development, corporate strategy, and corporate finance.

Hicham Alaoui Chief Scientific OfficerHe has led drug discovery and development programs for small molecules and biologics at Genentech and has experience advancing clinical candidates across multiple therapeutic areas with unmet medical needs.

Rose MarinoChief Medical OfficerChief Medical Officer at Glycomine www.glycomine.com

Peter McWilliamsChief Business OfficerVenture Partner at Sanderling Ventures

Geoffrey Hird Chief Technology OfficerWith 19 years of experience across small, medium, and large pharmaceutical companies, he has led CMC teams in drug product development and manufacturing, with expertise in surfactant science and formulation technologies including liposomes, lipid nanoparticles, and inhaled and oral delivery systems.

Board

Giacomo Chiesi Board Member2016–2019Managing Partner at Chiesi Ventures

Christopher StarrBoard director

Investors · 13

Advent Life Scienceslisted by Advent Life SciencesLondon

How we know: Advent Life Sciences's portfolio page · a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Asahi Kasei Corporate Venture Capitallisted by Asahi Kasei Corporate Venture CapitalMenlo Park · $200K – $5M

How we know: Asahi Kasei Corporate Venture Capital's portfolio page · Not right? Tell us

Chiesi Ventureslisted by Chiesi VenturesBoston · $5M

How we know: Chiesi Ventures's portfolio page · board seat on SEC Form D · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

CTI Life Sciences Fund L.P.listed by CTI Life Sciences Fund L.P.Montréal

How we know: CTI Life Sciences Fund L.P.'s portfolio page · funding news · Not right? Tell us

Mission Bay Capitallisted by Mission Bay CapitalSan Francisco

Mission Biocapitallisted by Mission BiocapitalSan Francisco · $500K

How we know: Mission Biocapital's portfolio page · funding news · the VCSheet dataset · Not right? Tell us

Remiges Ventures, Inc.listed by Remiges Ventures, Inc.Seattle

How we know: Remiges Ventures, Inc.'s portfolio page · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

RiverVest Venture Partnerslisted by RiverVest Venture PartnersSt. Louis · $500K – $3M

How we know: RiverVest Venture Partners's portfolio page · a partner's Signal profile · funding news · Not right? Tell us

Sanderling Ventureslisted by Sanderling VenturesSan Mateo · $50K – $1M

How we know: Sanderling Ventures's portfolio page · funding news · Not right? Tell us

Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M

How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

AbingworthreportedLondon · $15M – $30M

How we know: a partner's Signal profile · funding news · Not right? Tell us

abrdn plcreportedEdinburgh

How we know: funding news · Not right? Tell us

Novo HoldingsreportedCopenhagen · $1.1M – $54M

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

$234.9M disclosed across 3 of 5 rounds · 2016–2025

$115MSeries CApr 2025 · 2 sources
Source ↗
$115MraisedApr 2025 · 2 sources
Source ↗

▶$4.9MraisedNov 2016 · 15 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Christopher StarrDirector
Peter C.M. McWilliamsDirector
Agnes RafalkoExecutive Officer, Director
Giacomo ChiesiDirector

Offering amount: $12.6M
Amount sold: $4.9M
Minimum investment: $10K
First sale: Oct 2016
Incorporated: Corporation, Delaware, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

Myriad GeneticsMyriad Genetics is a genetic testing and precision medicine company that delivers molecular diagnostic test results across hereditary cancer risk, reproductive health, oncology, urology, and mental health. It serves patients and healthcare providers with insights to help detect, treat, and prevent disease.

Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Companies working in the same space as Glycomine.

Frequently asked questions

What does Glycomine do?: Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options. The company focuses on addressing unmet medical needs in the rare disease space.
Who founded Glycomine?: Glycomine was founded by Agnes Rafalko in 2014.
Who are Glycomine's investors?: Glycomine's investors include Advent Life Sciences, Asahi Kasei Corporate Venture Capital, Chiesi Ventures, CTI Life Sciences Fund L.P., Mission Bay Capital, Mission Biocapital, Remiges Ventures, Inc., RiverVest Venture Partners and 5 more.
How much funding has Glycomine raised?: Glycomine has disclosed $234.9M raised across 3 of its 5 known rounds.
Where is Glycomine headquartered?: Glycomine is headquartered in San Francisco, US.